This editorial is accompanies an article by van de Donk et al., Anaesthesia 2018; 73: [231‐7](http://dx.doi.org/10.1111/anae.14132).

You can respond to this article at <http://www.anaesthesiacorrespondence.com>

As a specialist in a field of medicine, occasionally one is obliged to read, and quite often re‐read, about aspects of your practise. In this instance, writing this editorial coincided with refreshing our knowledge regarding the literature on gabapentin. Therefore, coincidentally, we came across an article by Steinman et al. that reported how 'cleverly' industry promoted the anticonvulsant and antineuropathic drug gabapentin in the 1990s [1](#anae14037-bib-0001){ref-type="ref"}. For their article, Steinman et al. reviewed publicly available court documents from the USA and thus identified three main strategies industry employed to promote gabapentin. The first involved continuing medical educational activities targeting a wide audience, for instance organising local talks and lectures as well as meetings and conferences. The second approach, advisory boards and consultant meetings, was directed at opinion leaders and high‐rate anticonvulsant prescribers. Meetings were often held at luxury hotels and participants frequently received honoraria and travel reimbursements. Finally, Steinman et al. found even research and publication strategies '*served as key elements in the marketing for the drug \[gabapentin\]*'. Original articles, for instance, were not only used to gain US Food and Drug Administration (FDA) approval, but also as tools to '*disseminate information as widely as possible*'. Review articles and letters to the editor had the same purpose. Often, medical education companies were employed to guide or even directly prepare manuscripts ('ghost‐writing'), and to choose 'suitable authors'. 'Suitable authors' usually already had a commercial relationship with industry and/or were subsequently paid to participate in the publication process. Also, for some articles, sponsorship was not disclosed. Steinman et al. concluded that involving physicians in research and publication helped industry to engage opinion leaders, reward customers and influence prescribing.

Reflecting on Steinman\'s article and because of the recent, seemingly omnipresent, advertisements for the sufentanil sublingual tablet system (SSTS), we thought it prudent to gather more information about how the data presented in van de Donk et al.\'s review, published in this edition of the journal, were generated, whether they might be in any way biased, and whether any particular marketing strategy, that might resemble the process Steinman described, was apparent relating to SSTS [2](#anae14037-bib-0002){ref-type="ref"}.

Conflict of interest statements {#anae14037-sec-0002}
===============================

Because Steinman et al. also noted that industry‐sponsored original articles preferentially reported results favouring gabapentin, we think it is important review articles should always mention the conflict of interest (COI) statements of each work they include. Interestingly, this is not common practice yet and this struck us as odd. It seems reviews hardly ever provide information on COIs for the research they are basing their messages on. This is despite journals being increasingly diligent in disclosing COI statements for authors of original articles [3](#anae14037-bib-0003){ref-type="ref"}. Although the sense and (perhaps) nonsense of disclosing COIs is still controversial [4](#anae14037-bib-0004){ref-type="ref"}, [5](#anae14037-bib-0005){ref-type="ref"}, journals are right to ask for as much transparency as possible about potentially important sources of bias. This notion is not only based on evidence, that industry funded research more often than not favours the sponsor\'s product [6](#anae14037-bib-0006){ref-type="ref"}, [7](#anae14037-bib-0007){ref-type="ref"}, but simply reflects good research practice. By reporting as many confounders as possible, one allows others to reproduce the reported results [8](#anae14037-bib-0008){ref-type="ref"}. However, omitting such information in review articles, considered a beacon of evidence‐ based medicine [9](#anae14037-bib-0009){ref-type="ref"}, at best dilutes and at worst even contradicts the original journal editors' intentions.

To explore whether the non‐provision of individual COI disclosures is indeed standard practice in review articles, we performed a short, albeit crude, survey. On entering the following search terms into PubMed: 'review' (title/abstract) AND 'analgesia' (title/abstract) AND 'date of publication' (2015/01/01--2017/03/29), we retrieved n = 970 articles (accessed March 2017). We randomly selected 10% of these (n = 97 articles) to look at further; these included systematic and narrative reviews. Despite all articles having COI statements regarding their authors, and many including statements about evaluating the risk of bias in selected articles, none provided information about the funding of the trials they included. It is therefore laudable *Anaesthesia* asked van de Donk et al. to address the issue of industry funding for the four key articles included in their manuscript [10](#anae14037-bib-0010){ref-type="ref"}, [11](#anae14037-bib-0011){ref-type="ref"}, [12](#anae14037-bib-0012){ref-type="ref"}, [13](#anae14037-bib-0013){ref-type="ref"}. Regardless of whether single‐source funding of undertaken research constitutes an indication for systematically biased evidence, van de Donk et al.\'s statement according to Schwid and Gross [8](#anae14037-bib-0008){ref-type="ref"} thus '*ensures that everyone has as much information as possible to critically appraise each report*'. We hope this will serve as a precedent and will be widely adopted in the future.

Multiple reviews {#anae14037-sec-0003}
================

Further, looking through the retrieved titles of the Pubmed search, we were surprised to find seven review articles published between November 2015 and February 2017 regarding the use of sublingual sufentanil nanotablets for the treatment of pain [14](#anae14037-bib-0014){ref-type="ref"}, [15](#anae14037-bib-0015){ref-type="ref"}, [16](#anae14037-bib-0016){ref-type="ref"}, [17](#anae14037-bib-0017){ref-type="ref"}, [18](#anae14037-bib-0018){ref-type="ref"}, [19](#anae14037-bib-0019){ref-type="ref"}, [20](#anae14037-bib-0020){ref-type="ref"}. All seven reviews included the same original articles, sometimes citing each other [14](#anae14037-bib-0014){ref-type="ref"}, [15](#anae14037-bib-0015){ref-type="ref"}, [18](#anae14037-bib-0018){ref-type="ref"}, [19](#anae14037-bib-0019){ref-type="ref"} or providing the same figures [14](#anae14037-bib-0014){ref-type="ref"}, [17](#anae14037-bib-0017){ref-type="ref"}, [19](#anae14037-bib-0019){ref-type="ref"} or similar tables [14](#anae14037-bib-0014){ref-type="ref"}, [17](#anae14037-bib-0017){ref-type="ref"}, [19](#anae14037-bib-0019){ref-type="ref"}. The publication of seven reviews in 16 months, all independently reviewing the same evidence, led us to consider how many original publications about sublingual sufentanil existed altogether. A further PubMed search (search term: 'sublingual sufentanil' conducted in March 2017) identified seven original articles. Interestingly, they included the four papers cited in van de Donk et al.\'s review and importantly all seven articles were funded by the same company (AcelRx Pharmaceuticals Inc., Redwood City, CA, USA). Cross‐checking with the USA trial registry 'ClinicalTrials.gov' (<https://clinicaltrials.gov>; search term: 'sublingual sufentanil'), this company had completed 16 clinical trials with SSTS since March 2008. According to 'ClinicalTrials.gov', seven of these studies were still to be published (last accessed 9 April 2017) while nine appeared in the seven original articles found in the described PubMed search. Therefore, just seven original articles have now created eight reviews, including that of van de Donk et al. published in this issue of *Anaesthesia*.

According to Steinman et al.\'s article, it appears this is not uncommon practice as it apparently is an important part of industry\'s promotional strategy [1](#anae14037-bib-0001){ref-type="ref"}. Furthermore, clinical trials frequently cited within 2 years of their publication, are thought not only to endorse the product in question, but also help boost the impact factor of their publishing journals, creating a win‐win situation for all parties involved [21](#anae14037-bib-0021){ref-type="ref"}, [22](#anae14037-bib-0022){ref-type="ref"}.

As much as this discovery feels uneasy, it is important to reflect that although this appears to represent an uneven balance between review and original articles, there is nothing unlawful about this practice. Lexchin et al. outline that, although industry‐funded studies were more likely to favour industry\'s products [6](#anae14037-bib-0006){ref-type="ref"}, contrary to common belief, industry‐sponsored studies were at least of the same quality as studies supported by other sources [23](#anae14037-bib-0023){ref-type="ref"}. This is an important consideration in the current academic climate where research funding is diminishing, and new drugs are unlikely to be trialled outside of industry sponsorship.

Article quality {#anae14037-sec-0004}
===============

Therefore, industry sponsorship aside, are the four SSTS articles cited by van de Donk et al. [10](#anae14037-bib-0010){ref-type="ref"}, [11](#anae14037-bib-0011){ref-type="ref"}, [12](#anae14037-bib-0012){ref-type="ref"}, [13](#anae14037-bib-0013){ref-type="ref"} performed with adequate rigor? To evaluate this, 'quality indicators' as suggested by Sackett and Oxman [24](#anae14037-bib-0024){ref-type="ref"} as well as Bero and Rennie [25](#anae14037-bib-0025){ref-type="ref"} were considered to look at: the ethical approval process; the conduct of the research; and the overall quality of the manuscripts.

Ethical approval for the three clinical trials were sought in North Carolina [10](#anae14037-bib-0010){ref-type="ref"}, [11](#anae14037-bib-0011){ref-type="ref"}, [12](#anae14037-bib-0012){ref-type="ref"} and for the pharmacokinetic study in Kansas [13](#anae14037-bib-0013){ref-type="ref"}, respectively, despite the company marketing SSTS in the USA being based in California. Both these remote review boards are independent, non‐academic, for hire institutions (North Carolina: <http://www.cgirb.com/about/>; Kansas: <https://mlirb.com/>). The Kansas‐based Board also advertises its services using a statement from the first author of the sufentanil pharmacokinetic study (<https://mlirb.com/>: last accessed 12 April 2017). This complies with USA law, however seems at odds to European practice where there is extensive governmental policing and regulation.

With respect to the conduct of the individual studies, the descriptions of the randomisation and blinding processes within Jove\'s [11](#anae14037-bib-0011){ref-type="ref"}, Ringold\'s [12](#anae14037-bib-0012){ref-type="ref"} and Melson\'s [10](#anae14037-bib-0010){ref-type="ref"}, articles were brief. As highlighted by van de Donk et al., Melson\'s study was an open‐label trial. The group allocations for the other three blinded clinical trials took place in recovery following surgery, and after it had been confirmed patients were opioid‐sensitive or responders [10](#anae14037-bib-0010){ref-type="ref"}, [11](#anae14037-bib-0011){ref-type="ref"}, [12](#anae14037-bib-0012){ref-type="ref"}. This method is often adopted to ensure the study participant has a known response to the drug in question. However, it could allow for the possibility of biased patient selection. Further, Jove\'s and Ringold\'s studies compared sufentanil only with placebo, while Melson used an active comparator (intravenous morphine), albeit at a lower equivalent dose than the test drug. Both control group approaches have been criticised in the past and could contribute to a favourable trial drug outcome [6](#anae14037-bib-0006){ref-type="ref"}, [7](#anae14037-bib-0007){ref-type="ref"}, [25](#anae14037-bib-0025){ref-type="ref"}.

Finally, when judging the overall quality of the four original manuscripts, both the Jove [11](#anae14037-bib-0011){ref-type="ref"} and Willsie [13](#anae14037-bib-0013){ref-type="ref"} articles included the statement '*editorial assistance was provided...*'. This phrase, according to McHenry, indicates the involvement of a ghost‐writer and the possibility of '*misreporting of the data to favour the sponsor\'s product*' [22](#anae14037-bib-0022){ref-type="ref"}.

What is going on? {#anae14037-sec-0005}
=================

To summarise, the evidence regarding the sufentanil sublingual tablet system at present involves more reviews than original articles, the ethical approvals for these trials were granted by commercial review boards, the reporting of and some of the research methodology in the clinical trials contain some shortcomings, and for the preparation of two manuscripts, ghost‐writers were employed. Hence, there is the possibility that SSTS is being subjected to a promotional tool similar to that seen with gabapentin described by Steinman et al. [1](#anae14037-bib-0001){ref-type="ref"}.

However, we also think this case likely reflects a deeper‐seated issue regarding research and publishing, where all stakeholders contribute to the problem. As, for instance, at the moment, the tables are turning in the epic race between fraudsters and journals favouring the latter, the onus is more than ever on authors [26](#anae14037-bib-0026){ref-type="ref"}, [27](#anae14037-bib-0027){ref-type="ref"}. This is highlighted by a recent example of the use of statistics in this journal [28](#anae14037-bib-0028){ref-type="ref"}.

Moreover, journals, far from being the victims, may contribute themselves. Due to their own financial interests, they can become biased also. As Lundh et al. highlight [21](#anae14037-bib-0021){ref-type="ref"}, journals like publishing industry‐funded trials, because firstly they are cited more frequently and hence help boost a journal\'s impact factor, and secondly companies often purchase large numbers of reprints which for some journals constitute a considerable part of their total income [21](#anae14037-bib-0021){ref-type="ref"}. An extreme example of this is the creation of journals for the sole purpose of product promotion [29](#anae14037-bib-0029){ref-type="ref"}. Furthermore, some open access e‐journals (so called 'predatory journals') are financed by offering prompt publication, often at the expense of a proper review process, in exchange for considerable fees [30](#anae14037-bib-0030){ref-type="ref"}. Even the peer review process, potentially the gate keeper to research integrity, has recently been tainted following a publisher needing to retract 43 papers due to allegations of the peer review process being inappropriately influenced and compromised [31](#anae14037-bib-0031){ref-type="ref"}. Finally, studies reaching the mainstream media may preferentially report research regarding lifestyle issues that have 'positive' data [32](#anae14037-bib-0032){ref-type="ref"}. Therefore, more or less, we all are responsible for the shortcomings in medical research reporting, and currently as readers we search for a way through a dizzying maze of conflicting interests and ever increasing moral expectations. To be fair, some authors have started developing ideas of how to address these issues, but they will take time to be adopted as they involve a complete change of culture [33](#anae14037-bib-0033){ref-type="ref"}, [34](#anae14037-bib-0034){ref-type="ref"}, [35](#anae14037-bib-0035){ref-type="ref"}, [36](#anae14037-bib-0036){ref-type="ref"}.

So, how can we address this complex issue currently? As readers, as reviewers and as authors, we need to insist on an academic standard by asking for more transparency. If we don\'t understand, we should ask for it to be explained and if it doesn\'t seem plausible, we should ask for the data to show it is. In other words, we need to step back, be curious and cast a critical eye.
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